82 related articles for article (PubMed ID: 2022266)
1. Increased circulating levels of bromocriptine after vaginal compared with oral administration.
Katz E; Weiss BE; Hassell A; Schran HF; Adashi EY
Fertil Steril; 1991 May; 55(5):882-4. PubMed ID: 2022266
[TBL] [Abstract][Full Text] [Related]
2. Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women.
Vermesh M; Fossum GT; Kletzky OA
Obstet Gynecol; 1988 Nov; 72(5):693-8. PubMed ID: 3173919
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia.
Kletzky OA; Vermesh M
Fertil Steril; 1989 Feb; 51(2):269-72. PubMed ID: 2912773
[TBL] [Abstract][Full Text] [Related]
4. Superiority of newly developed vaginal suppositories over vaginal use of commercial bromocriptine tablets: a randomized controlled clinical trial.
Darwish AM; Farah E; Gadallah WA; Mohammad II
Reprod Sci; 2007 Apr; 14(3):280-5. PubMed ID: 17636242
[TBL] [Abstract][Full Text] [Related]
5. Vaginal bromocriptine--clinical and biochemical effects.
Ginsburg J; Hardiman P; Thomas M
Gynecol Endocrinol; 1992 Jun; 6(2):119-26. PubMed ID: 1502929
[TBL] [Abstract][Full Text] [Related]
6. Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women.
Cicinelli E; Cignarelli M; Petruzzi D; Matteo MG; Ruccia C; Schonauer LM
J Endocrinol Invest; 1996; 19(7):427-32. PubMed ID: 8884536
[TBL] [Abstract][Full Text] [Related]
7. Prolactin (PRL) response to oral or vaginal bromoergocriptine in hyperprolactinemic women.
Dash RJ; Ajmani AK; Sialy R
Horm Metab Res; 1994 Mar; 26(3):164. PubMed ID: 8005568
[No Abstract] [Full Text] [Related]
8. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia.
Darwish AM; El-Sayed AM; El-Harras SA; Khaled KA; Ismail MA
Fertil Steril; 2008 Nov; 90(5):1864-8. PubMed ID: 18462734
[TBL] [Abstract][Full Text] [Related]
10. Clinical and hormonal response to short-term intermittent versus continuous oral bromocriptine in hyperprolactinemic women.
Parra A; Crespo G; Coria I; Espinosa de los Monteros A
Int J Fertil Menopausal Stud; 1995; 40(2):96-101. PubMed ID: 7599666
[TBL] [Abstract][Full Text] [Related]
11. A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
Gianola D; Pedroncelli A; Montini M; Tengattini F; Pagani MD; Cortesi L; Cappi MP; Gherardi F; Lancranjan I; Pagani G
Gynecol Endocrinol; 1991 Sep; 5(3):213-6. PubMed ID: 1776507
[TBL] [Abstract][Full Text] [Related]
12. [Study on hyperprolactinemic anovulatory syndrome and treatment with bromocriptine (author's transl)].
Fukunaga T
Acta Obstet Gynaecol Jpn; 1981 Feb; 33(2):229-38. PubMed ID: 7015779
[TBL] [Abstract][Full Text] [Related]
13. Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.
Moro M; Maraschini C; Toja P; Masala A; Alagna S; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Horm Res; 1991; 35(3-4):137-41. PubMed ID: 1806467
[TBL] [Abstract][Full Text] [Related]
14. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects.
Schiebinger RJ; Chrousos GP; Cutler GB; Loriaux DL
J Clin Endocrinol Metab; 1986 Jan; 62(1):202-9. PubMed ID: 2999177
[TBL] [Abstract][Full Text] [Related]
15. Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia.
Weingrill CO; Mussio W; Moraes CR; Portes E; Castro RC; Lengyel AM
Fertil Steril; 1992 Feb; 57(2):331-5. PubMed ID: 1735484
[TBL] [Abstract][Full Text] [Related]
16. Nasal spray bromocriptine: effects on serum prolactin in puerperal women.
Cicinelli E; Petruzzi D; Ragno G; Schönauer LM; Ruccia C; Matteo G
Acta Obstet Gynecol Scand; 1996 Sep; 75(8):730-3. PubMed ID: 8906007
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydergine in hyperprolactinemia.
Tamura T; Satoh T; Minakami H; Tamada T
J Clin Endocrinol Metab; 1989 Aug; 69(2):470-4. PubMed ID: 2753986
[TBL] [Abstract][Full Text] [Related]
18. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia.
Ciccarelli E; Mazza E; Ghigo E; Guidoni F; Barberis A; Massara F; Camanni F
J Endocrinol Invest; 1987 Feb; 10(1):51-3. PubMed ID: 3598074
[TBL] [Abstract][Full Text] [Related]
19. Nasal spray administration of bromocriptine: pharmacology and effect on serum prolactin level in puerperal women.
Cicinelli E; Cignarelli M; Petruzzi D; Matteo G; Ruccia C; Schonauer LM
Gynecol Endocrinol; 1996 Dec; 10(6):391-6. PubMed ID: 9032565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a new long-acting injectable form of bromocriptine in hyperprolactinaemic patients.
Pagani MD; Tengattini F; Montini M; Pagani G; Pedroncelli A; Gianola D; Gherardi F; Mazzocchi N; Cortesi L; Lancranjan I
Clin Endocrinol (Oxf); 1992 Apr; 36(4):369-74. PubMed ID: 1424170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
